Segment
Type of investment
Divested companies
Flerie encourages partnerships and M&A activity to accelerate bringing treatments to patients. When this results in an acquisition, proceeds are reallocated to the investment pool in line with our evergreen strategy.
![flerie-wilson-logo-bw](https://www.flerie.com/en/wp-content/uploads/sites/2/2023/03/flerie-wilson-logo-bw.png)
![flerie-wilson-logo-bw-overlay](https://www.flerie.com/en/wp-content/uploads/sites/2/2023/03/flerie-wilson-logo-bw-overlay.png)
Wilson Therapeutics
Wilson Therapeutics was a biopharmaceutical company, based in Stockholm, Sweden, developing novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics' product, WTX101, was in Phase 3 development as a novel treatment for Wilson disease when it was acquired by Alexion in 2018.